OTCMKTS:DGNOF

DIAGNOS (DGNOF) Stock Price, News & Analysis

$0.21
0.00 (-2.11%)
(As of 04/26/2024 04:16 PM ET)
Today's Range
$0.21
$0.21
50-Day Range
$0.18
$0.25
52-Week Range
$0.18
$0.43
Volume
30,500 shs
Average Volume
44,894 shs
Market Capitalization
$16.00 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
DGNOF stock logo

About DIAGNOS Stock (OTCMKTS:DGNOF)

DIAGNOS Inc. provides software-based services primarily in Canada, the United States, Colombia, Spain, Mexico, Saudi Arabia, and Costa Rica. The company offers healthcare services through Computer Assisted Retina Analysis, a web-based software tool that assists healthcare professionals for the detection of diabetic retinopathy; and allows eye care specialist to visualize both normal retinal landmarks and pathological changes. It also provides various consulting services in the fields of data analysis and artificial intelligence. DIAGNOS Inc. was founded in 1998 and is headquartered in Brossard, Canada.

DGNOF Stock Price History

DGNOF Stock News Headlines

DIAGNOS (OTCMKTS:DGNOF) Trading Down 0.7%
Did You Get Your Free Bitcoin Yet?
And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.
DIAGNOS Announces Grant of Stock Options
DIAGNOS Announces Grant of Stock Options
Did You Get Your Free Bitcoin Yet?
And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.
DIAGNOS recognized as a Top TSX Venture Exchange Company
Best of 2023
See More Headlines
Receive DGNOF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for DIAGNOS and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/28/2024
Today
4/27/2024
Fiscal Year End
3/31/2025

Industry, Sector and Symbol

Industry
Private households
Sub-Industry
N/A
Current Symbol
OTCMKTS:DGNOF
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Net Income
$-1,880,000.00
Net Margins
-1,553.79%
Pretax Margin
-1,032.49%

Debt

Sales & Book Value

Annual Sales
$370,000.00
Book Value
($0.02) per share

Miscellaneous

Free Float
N/A
Market Cap
$16.00 million
Optionable
Not Optionable
Beta
0.20
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Mr. Andre Larente
    CEO, President & Executive Chairman
  • Mr. Marc-André Massue
    VP of Finance, CFO & Secretary
  • Mr. Yves-Stéphane Couture
    Chief Operating Officer
  • Mr. Martin Beland
    Director of Marketing

DGNOF Stock Analysis - Frequently Asked Questions

How have DGNOF shares performed in 2024?

DIAGNOS's stock was trading at $0.3050 at the beginning of the year. Since then, DGNOF stock has decreased by 31.5% and is now trading at $0.2088.
View the best growth stocks for 2024 here
.

How were DIAGNOS's earnings last quarter?

DIAGNOS Inc. (OTCMKTS:DGNOF) announced its quarterly earnings results on Wednesday, February, 28th. The company reported ($0.01) EPS for the quarter. The business earned $0.04 million during the quarter.

How do I buy shares of DIAGNOS?

Shares of DGNOF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:DGNOF) was last updated on 4/27/2024 by MarketBeat.com Staff

From Our Partners